Back
Return
Biography
Dr. Wei-Zhu Zhong
Dr. Weizhu Zhong

Department of Pharmacokinetics, Dynamics and Metabolism

Pfizer Global Research and Development, USA

Associate Research Fellow


Email: wei-zhu.zhong@pfizer.com


Qualifications

1981 Postdoctoral Research Fellow, chemical center, Lund University, Sweden


Publications (Selected)

  1. Zhong WZ, Zhan J, Kang P, Yamazaki S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr Drug Metab 2010, 11(4), 296.
  2. Nguyen L, Zhong WZ, Painter CL, Zhang C, Rahavendran AV, Shen Z. Quantitative Analysis of PD 0332991, A Cyclin-dependent Kinase inhibitor, in Xennograft Mouse Tumor Tissue by Supported Liquid Extraction Coupled with Liquid Chromatography/Mass Spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2010, 53(3), 228-234.
  3. Zhong WZ, Lalovic B, Zhan J. Characterization of In Vitro and In Vivo Metabolism of AG-024322, a Novel Cyclin-Dependent Kinase (CDK) Inhibitor. Health 2009, 1(4), 249-262.
  4. Chou KC, Cai YD, Zhong WZ. Predicting networking couples for metabolic pathways of Arabidopsis. EXCLI Journal 2006; 5, 55-65.
  5. Bai Y, Wang D, Yu ZX, Jia Y, Zhu FU, Wei DQ, Zhong WZ, and Chou KC. Ecdysterone Determination of Niuxi by Near-Infrared Diffuse Reflection Spectroscopy. Spectroscopy 2006, 21 (2).
  6. Chou KC, Wei DQ, Zhong WZ: Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 2003, 308: 148-151.
  7. Williams MG, Shobe EM, Bothwell BE, and Zhong WZ. Development of a sensitive bioanalytical method for determination of PNU-83757 in rat, monkey and human plasma: from LC-UV to LC-MS/MS. Journal of Pharmaceutical & Biomedical Analysis 2002, 30, 429-441.
  8. Zhong WZ, Williams MG, Brastetter DG. Toxicokinetics in drug development: An overview of toxicokinetic application in the development of PNU-101017, an anxiolytic drug candidate. Current Drug Metabolism, 2000, Vol.1, No.3, 243-254.
  9. Zhong WZ, Williams MG. Enantiospecific determination of PNU-83894 and its major metabolite, PNU-83892, in plasma and its application in characterization of enantioselective pharmacokinetics of PNU-83894 in the dog. Journal of Chromatography A 2000, 871, 201‑206.
  10. Zhong WZ. Application of solid-phase extraction in the method development for determination of SEPA in human, rat, and rabbit serum using GC-FID method. Journal of Pharmaceutical & Biomedical Analysis 1998, 16, 1179-1187.
  11. Zhong WZ, Williams MG, Borin MT, Padbury GE. Species-dependent enantioselective pharmacokinetics of U‑103017, a pyrone HIV protease inhibitor, Chirality 1998, 10, 210-216.
  12. Zhong WZ, Sanders PE, Hauer MJ, Vrbanac JJ,. Quantirative analysis of 2-nnonyl-1,3-dioxolane by stable-isotope dilution gas chromatography-mass spectrometry. Journal of Chromatography B 1998, 705, 39-45.
  13. Williams MG, Zhong WZ. Stereospecific determination of U-103017 in rat, dog, and human plasma using a pirkle-concept HPLC column. Journal of Chromatography B 1997, 694, 169-177.
  14. Mesfin GM, Higgins MJ, Robinson FG, and Zhong WZ. The relationship between serum concentrations, hemodynamic effects and cardiovascular lesions in dogs treated with minoxidil. Toxicol. Appl. Pharmacol. 1996, 140, 337-344.
  15. Zhong WZ, Williams MG, Schuette MR, VandeGiessen TL and Jones BW. Pharmacokinetics of the individual enantiomers of cis-3,4‑dichloro‑N‑methyl‑ N‑[2‑(1‑pyrrolidinyl)‑cyclohexyl]‑benzamide monohydrochloride (U-54494A) in the Dog. Enantiomer, 1996, 1, 89-96.
  16. Zhong WZ and Williams MG. Simultaneous Quantitation of Pioglitazone and its Metabolites in Human Serum by Liquid Chromatography and Solid Phase Extraction. Journal of Pharmaceutical & Biomedical Analysis 1996, 14 (4), 465-473.
  17. Zhong WZ, Williams MG, Cook KJ, VandeGiessen TL, Jones BW, Rousch KE. First-Pass Effect of cis- 3,4‑dichloro‑ N‑methyl‑N‑ (2‑(1‑pyrrolidinyl)‑ cyclohexyl)‑benzamide (U‑54494) in rats - A rat model with multiple cannulas for Investigation of gastrointestinal and hepatic metabolism. Pharmaceutical Research 1994, 11 (11), 1524-1529.
  18. Zhong WZ. Application of Solid Phase Extraction in Determination of U-82217 in Rat Serum, Urine, and Brain, Journal of Chromatography 1993, 629, 83-87.
  19. Williams MG and Zhong WZ. Determination of U-85575 in rat serum by solid-phase extraction and high-performance liquid chromatography, Journal of Liquid Chromatography 1993, 16 (3), 743-763.
  20. Zhong WZ. Determination of 6-chloro-3-(3-cyclopropyl 1,2,4,-oxadiazol-5-yl)-5-methyl-imidazo<1,5-a-quinoxalin-4(5h)-one in rat serum, urine, and brain by solid-phase extraction and liquid chromatography , Journal of Pharmaceutical & Biomedical Analysis 1991, 9, 573-580.
  21. Zhong WZ and Lakings DB. Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detection. Journal of Chromatography 1989, 490, 377-385.
  22. Lemley AT, Wagenet RJ and Zhong WZ. Sorption and Degradation of Aldicarb and its Oxidation Products in a Soil‑ water Flow System as a Function of pH and Temperature'', Journal of Environmental Quality 1988, 17 (3), 408‑414.
  23. Zhong WZ, Lemley AT and Spalik J. Quantitative determination of ppb levels of carbamate pesticides in water by capillary gas‑chromatography, Journal of Chromatography 1984, 299, 269‑274.
  24. Lemley AT and Zhong WZ. Kinetics of aqueous base and acid hydrolysis of aldicarb, aldicarb sulfoxide and aldicarb sulfone, Journal of Environmental Science and Health, 1983, B18(2), 189‑206.